# BI-2852

Cat. No.:	HY-126247	-
CAS No.:	2375482-51-0	
Molecular Formula:	C <sub>31</sub> H <sub>28</sub> N <sub>6</sub> O <sub>2</sub>	н
Molecular Weight:	516.59	Ň
Target:	Ras	
Pathway:	GPCR/G Protein	<u>}</u>
Storage:	4°C, stored under nitrogen	но
	* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)	

## SOLVENT & SOLUBILITY

In Vitro		ng/mL (106.47 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	1.9358 mL	9.6789 mL	19.3577 mL		
		5 mM	0.3872 mL	1.9358 mL	3.8715 mL		
		10 mM	0.1936 mL	0.9679 mL	1.9358 mL		
	Please refer to the so	solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution						
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution					
		dd each solvent one by one: 10% DMSO >> 90% corn oil solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution					

BIOLOGICAL ACTIVITY							
Description	BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.						
IC₅₀ & Target	KRAS(G12C) 450 nM (IC <sub>50</sub> )	KRAS(G12C) 750 nM (Kd)					
In Vitro	BI-2852 (Compound 1) (10 nM-10 $\mu\text{M}$ ; 2 hours) shows a dose-dependent pERK modulation and antiproliferative						

ŅΗ



## s of 5.8 $\mu\text{M}$ and 6.7 $\mu\text{M}$ in soft agar and low serum conditions in NCI-H358 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Kessler D, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019 Aug 6; 116(32):15823-15829.

[2]. Dirk Kessler, et al. Drugging all RAS isoforms with one pocket. FUTURE MEDICINAL CHEMISTRY

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA